share_log
Moomoo 24/7 ·  Mar 28 11:45
Immuneering Shares Are Trading Higher. The Company Yesterday Announced That the First Patient Has Been Dosed in Its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment